Hematology-Oncology Clinical Trials
The following searchable list includes all the Division of Hematology-Oncology - Department of Medicine clinical trials currently looking for participants. Please feel free to contact us with inquiries about any of our ongoing research.
Back to top
Effects of Intravenous Ferric Carboxymaltose on Phosphorus and FGF23 Levels
Our research group is currently conducting a 6-8 -week study on patients with iron deficiency anemia to determine the effect of treating iron deficiency anemia with intravenous ferric carboxymaltose therapy on FGF23 and phosp…
Our research group is currently conducting a 6-8 -week study on patients with iron deficiency anemia to determine the effect of treating iron deficiency anemia with intravenous ferric carboxymaltose therapy on FGF23 and phosphorus levels. A single dose of ferric carboxymaltose has been shown to increase FGF23 levels in the short-term, but the long-term effects of ferric carboxymaltose on FGF23 levels in iron deficient patients are not known. We are conducting this research study to understand the effects of intravenous ferric carboxymaltose therapy on blood levels of FGF23 in individuals with iron deficiency anemia. The information gained from this study could be used to improve the health of patients with iron deficiency anemia.
Receiving 2 doses of injectafer from Bleeding clinic
BTCRC GYN15-013: Phase II Study of Pembrolizumab in Combination with Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
The purpose of this study is to test the good and bad effects of the study drug, pembrolizumab, in combination with routine care using paclitaxel and ca…
The purpose of this study is to test the good and bad effects of the study drug, pembrolizumab, in combination with routine care using paclitaxel and carboplatin chemotherapy.
DRUG CA209-816: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
The main purpose of this study is to look at the safety, tolerability, and overall effectiveness (how well the …
The main purpose of this study is to look at the safety, tolerability, and overall effectiveness (how well the drug works) of nivolumab in combination with ipilimumab and nivolumab in combination with plantinum doublet chemotherapy in subjects with non-small cell lung cancer.
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
This research study is investigating a drug (that is called IMCgp100) in patients with a…
This research study is investigating a drug (that is called IMCgp100) in patients with advanced uveal melanoma. Uveal melanoma is generally treated with either chemotherapy or drugs that work by activating the immune system, known as immunotherapies. In this research study, IMCgp100 will be compared to three representative standard treatments: dacarbazine (a chemotherapy drug), ipilimumab (an immunotherapy drug targeting a protein called CTLA-4), or pembrolizumab (an immunotherapy drug targeting a protein called PD-1). This research study is being done to assess the efficacy and safety of the IMCgp100 in patients with uveal melanoma in comparison to these standard treatments.
A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant Avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with clinically detected lymph node metastases
The purpose of this study is to find out how Avelumab works in subjects who have Merkel Cell Carcino…
The purpose of this study is to find out how Avelumab works in subjects who have Merkel Cell Carcinoma (MCC) that has traveled to lymph nodes. Avelumab is being tested to see if it is given after surgery and radiation, if it might prevent the cancer from coming back. We are studying avelumab (anti-PDL-1, also called MSB0010718C). Avelumab is currently approved by the Food and Drug Administration for the treatment of advanced and metastatic MCC. This FDA approval of avelumab for patients with advanced MCC was granted on the basis of a phase II study showing activity when given after progression of disease on chemotherapy. However, avelumab is an experimental drug in this study and it has NOT been approved for treatment of MCC that has traveled to the lymph nodes (node-positive, non-metastatic MCC) that has been removed with surgery. Avelumab has not been tested in this setting before. Participants will be randomly assigned to be given either avelumab or a placebo. The avelumab and placebo will be given by intravenous (IV) infusion. In the study, the avelumab or placebo will be given every 2 weeks for the first 4 months (Induction Phase 1), then once a month for 4 months (Induction Phase 2), and then once every 3 months for up to 2 years (Maintenance Phase). Participants will continue to receive treatment depending on how they tolerate the study drug and how their cancer responds. After completing all study treatments or after the study has been stopped for other reasons, participants will be asked to continue with follow-up visits to monitor for potential benefits or side effects they may be experiencing from study treatment. Participants may be followed for up to 3 years after finishing study treatment.
Participants must be at least 18 years of age or older. Participants must have Merkel Cell Carcinoma metastases in lymph node(s). Participants must have completed treatment that included surgical removal of the MCC metastases.